Safety Information and Unanticipated Problems Reporting

Similar documents
IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events

The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial

Comprehensive Study Documents List (Biomedical Studies)

Investigator responsibilities for research conducted under the authority of the UTHSCSA Institutional Review Board (IRB)

Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute

Reliance Agreement for Institutions Utilizing Stony Brook University s Institutional Review Board(s)

Adverse Events in Clinical Trials: Definitions and Documentation

Data Management in Clinical Trials

12.0 Investigator Responsibilities

Yale Cancer Center Data and Safety Monitoring Committee Charter

INVESTIGATOR HANDBOOK

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

Vertex Investigator-Initiated Studies Program Overview

Principal Investigator Responsibilities for Education and Social/Behavioral Researchers

Essential Standard Operating Procedures Sample Templates Table of Contents

ROLE OF THE RESEARCH COORDINATOR Study Start-up Best Practices

Guidance on IRB Continuing Review of Research

Effective Date: October 2015

Quality Monitoring Checklist

PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE

University of California Davis. Investigator Manual. Revised March 10, 2016

Tracy Walker, RN, BSN, CCRP Research Nurse OHSU Knight Cancer Institute

Principal Investigator and Sub Investigator Responsibilities

Standard Operating Procedures

Guidance for IRBs, Clinical Investigators, and Sponsors. Considerations When Transferring Clinical Investigation Oversight to Another IRB

Essential Documents for the Conduct of a Clinical Trial. Debra Dykhuis Associate Director RSO

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Data Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.

Guidance for Industry Investigator Responsibilities Protecting the Rights, Safety, and Welfare of Study Subjects

Page 191 TITLE 21 FOOD AND DRUGS 355 1

Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions

Adverse Events: Documenting, Recording, and Reporting

A Principal Investigator s Guide to Responsibilities, Qualifications, Records and Documentation of Human Research University of Kentucky

CLINICAL RESEARCH ROLES CLINICAL RESEARCH ROLESCLINICAL RESEARCH ROLES

This policy applies to all clinical research conducted at Beaumont Health System.

STANDARD OPERATING PROCEDURE FOR RESEARCH. 2. Notification of Serious Breaches of Good Clinical Practice or Study Protocol

POLICY SUBJECT: EFFECTIVE DATE: 5/31/2013. To be reviewed at least annually by the Ethics & Compliance Committee COMPLIANCE PLAN OVERVIEW

Standard Operating Procedures (SOP) for: Reporting of Serious Breaches of GCP or the Trial Protocol sponsored CTIMP s. Lisa Austin, Research Manager

COUPONS.COM INCORPORATED CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS

Investigator Handbook to Human Research Activities. South Shore Hospital

The role, duties and responsibilities of clinical trials personnel Monitoring: rules and recommendations

Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity

Health Canada s GCP Compliance Program Part 2. GCP Information Sessions November 2010

Good Documentation Practices

Role of IRB/IEC in GCP. Benjamin Kuo, MD, Dr.PH, CIP.

IRB Submissions and Human Subjects Research Compliance. Georgia Health Sciences University

STANDARD OPERATING PROCEDURES FOR GOOD CLINICAL PRACTICE

Serious Breaches. Ian Gravenor. Senior Clinical Project Manager Novo Nordisk Ltd

GOOD CLINICAL PRACTICE: CONSOLIDATED GUIDELINE

Clinical Trials and Safety Surveillance of Drugs in Development

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives

Quality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work

Guidance for IRBs, Clinical Investigators, and Sponsors

PREP Course #27: Medical Device Clinical Trial Management

Regulatory Binder Instructions 25 April 2016

River Valley Therapy & Sports Medicine, Inc. Notice of Privacy Practices

Medicine Safety Glossary

Catherine Jahrsdorfer, RN, BSN Director of Clinical Services USF Health Office of Clinical Research

The Study Site Master File and Essential Documents

DHHS/NIH/OD/OIR/OHSRP 1/2/2015

CLINICAL DATA MONITORING PLAN (CDMoP) PROTOCOL # [0000] [TITLE]

Atlanta Insomnia & Behavioral Health Services, P.C. 315 West Ponce de Leon Ave Suite 1051 Decatur, GA

Documentation of the Informed Consent Process. USC Office for the Protection of Research Subjects (OPRS)

Northwest Cardiology Associates 400 W. Northwest Hwy Barrington, IL Fax HIPAA Notice of Privacy Practices ( Notice )

NOTICE OF THE NATHAN ADELSON HOSPICE PRIVACY PRACTICES

NOTICE OF PRIVACY PRACTICES TEMPLATE. Sections highlighted in yellow are optional sections, depending on if applicable

HIPAA Notice of Patient Privacy Practices

Health Products and Food Branch.

Guidance for Clinical Investigators, Sponsors, and IRBs

Data Safety Monitoring and the IRB. Bertha delanda IRB Training Specialist Research Compliance Office February 2011

STAR*D: Sequenced Treatment Alternatives to Relieve Depression Data Collection Procedures for Cognitive Therapists

Guide for Research Sites Seeking Accreditation

AAHRPP DOCUMENT # 84 UNIVERSITY OF ALABAMA HUMAN RESEARCH PROTECTIONS PROGRAM FORM: NOTIFICATION TO IRB OF EMERGENCY USE OF A TEST ARTICLE

CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:

Dr. Adam Apfelblat 5140 Highland Road Waterford Phone: (248) Fax: (248)

Industry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels

11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.

RULES FOR LAWYER DISCIPLINARY ENFORCEMENT OF THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF LOUISIANA

HIPAA Notice of Privacy Practices

Version history Version number Version date Effective date 01 dd-mon-yyyy dd-mon-yyyy 02 dd-mon-yyyy dd-mon-yyyy 03 (current) dd-mon-yyyy dd-mon-yyyy

Clinical Investigator Inspections and FDA-483 Observations

Pre-Questions. Mastering Clinical Research July 29, 2015

TEMPLATE DATA MANAGEMENT PLAN

IMMUNOTEC INC. AUDIT AND DISCLOSURE POLICY MANAGEMENT COMMITTEE CHARTER AND WHISTLEBLOWER POLICY

Managing Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey

REPRODUCTIVE BIOLOGY ASSOCIATES, LLP HIPAA MANUAL NOTICE OF PRIVACY PRACTICES

Good Clinical Practice 101: An Introduction

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)

CNE Disclosures. To change this title, go to Notes Master

Guidance on Withdrawal of Subjects from Research: Data Retention and Other Related Issues

A New Standard for Medical Device Adverse Event Classification

Health Insurance Portability and Accountability Act (HIPAA)

GUIDELINES ON MEDICAL DEVICES

ROLES, RESPONSIBILITIES AND DELEGATION OF DUTIES IN CLINICAL TRIALS OF MEDICINAL PRODUCTS

Understanding Your Health Record Information

INTERIM SITE MONITORING PROCEDURE

Transcription:

Safety Information and Unanticipated Problems Reporting

Objectives This presentation will address the following issues: What events must be promptly reported to the Quorum Review Institutional Review Board (IRB/REB). When and how such events must be reported. Why it is important to promptly report certain reports to the Board. How to report serious events, major protocol deviations, and other unanticipated problems to the IRB/REB.

Investigators confront a variety of events that may be reportable to the sponsor of the research or the IRB/REB Unrelated adverse events Expected adverse events Minor adverse events Significant adverse events Major protocol deviations Minor protocol deviations New safety information Unanticipated Problems

Sponsors and IRB/REBs have different regulatory reporting requirements Sponsor Regulations require sponsors to monitor all adverse events (AEs) experienced by a study s participants. IRB/REB Regulations require an IRB/REB to develop procedures to ensure prompt reporting of unanticipated problems involving risk to human subjects or others.

Sponsors monitor all adverse events experienced by a study s participants Sponsors monitor minor, serious, expected, unexpected, related and unrelated AEs. Sponsor perform data analysis and trending for the study Sometimes sponsors delegate data monitoring to a separate entity, such as a data safety monitoring board ( DSMB ). Sponsors must report their findings at least annually to the FDA

Investigator reporting requirements to sponsors and IRB/REBs are different Investigator Investigators generally must report all adverse events to the sponsor of the clinical trial. The investigator s reporting requirements are set forth in regulation and the protocol for the study. IRB/REB Investigators must report all unanticipated problems involving risk to participants or others to the IRB/REB.

Unanticipated problem is not defined by regulation The regulations do not provide a definition for unanticipated problems involving risk to human subjects or others. IRB/REBs must establish their own definition and procedures for investigators to report unanticipated problems

Quorum s definition of an unanticipated problem An unanticipated problem is an event that adversely affects: the risk/benefit ratio of the study; the rights, safety or welfare of the participants; or the integrity of the study Unanticipated is defined as: not identified in nature, severity, or frequency in the relevant safety document(s) for the study product or is not identified as a possible risk in the study protocol or the informed consent form for the study.

Prompt reporting of unanticipated problems allows the IRB/REB to decide whether: The risk/benefit ratio of the study is still acceptable given the new information Modifications should be made to the study to minimize risk to participants Participants should be informed of new information, potential risks, or other findings The study should be suspended or terminated

Quorum s policy regarding reportable events Quorum s position is that only unanticipated problems involving risk to subjects or others are reportable events that must be reported promptly to the IRB/REB. A reportable event must be reported within 10 business days of the investigator becoming aware of the event. Reportable events must be reported using Quorum s report forms.

Report only unanticipated problems involving risk to participants or others All Events/Problems Encountered during a Research Study Unanticipated problems involving risk to participants or others Protocol Deviations Adverse Events

What events to report Serious Adverse Events Major Protocol Deviations/Violations Other reportable events as defined by Quorum

What events to report a closer look Serious Adverse Events Major Protocol Deviations/Violations Other reportable events as defined by Quorum

Quorum s Definition of a Serious Adverse Event (SAE) A Serious Adverse Event* (SAE) is an adverse event that, in the investigator s judgment is: Serious, Unanticipated, and At least possibly related to study procedures or the study drug product Unanticipated problems involving risk to participants or others Adverse Events Serious Adverse Events *Quorum s definition of an SAE is not the same as the definition used by sponsors and within the clinical research industry. IND safety reports, CIOMS reports, and MedWatch reports do not automatically meet Quorum s reporting requirements for an SAE. Only those that reveal an unanticipated problem involving risk to participants or others should be reported.

What makes an SAE serious? In the investigator s judgment it Results in death Is life threatening (places the participant at immediate risk of death) Results in persistent or significant disability/incapacity (a substantial disruption of the participant s ability to conduct normal life functions) Results in, or prolongs inpatient hospitalization Is a congenital anomaly/birth defect, or Jeopardizes the participant or requires intervention to prevent one of the other outcomes listed here

Quorum s policy on reporting SAEs to the IRB / REB An investigator should report to the IRB / REB all serious adverse events that occur at his or her site. Unanticipated problems involving risk to participants or others Adverse Events Serious Adverse Events

Investigators do not need to report minor, expected, or unrelated adverse events to the IRB/REB Non-reportable Adverse Events Unanticipated problems involving risk to participants or others Adverse Events Examples of adverse events not considered reportable: A minor headache, even if probably caused by the study drug A worsening of the underlying disease condition, if such worsening was expected A MedWatch report that, in the PI s judgment, reports a risk that is probably not related to the PI s study

What events to report a closer look Serious Adverse Events Major Protocol Deviations/Violations Other reportable events as defined by Quorum

Quorum s Definition of a Major Protocol Deviation/Violation A Major Protocol Deviation/Violation, is a deviation or violation that adversely affects: risk/benefit ratio of the study; the safety, rights or welfare of participants or others; or the integrity of the study. Major Protocol Deviations/Violations Protocol Deviations Unanticipated problems involving risk to participants or others

Quorum s policy on reporting Major Protocol Deviations Major Protocol Deviations/Violations An investigator should report to the IRB/REB all Major Protocol Deviations/ Violations that occur at his or her site. Protocol Deviations Unanticipated problems involving risk to participants or others

Report only Major Protocol Deviations/Violations to the IRB/REB Examples of Major Protocol Deviations/Violations: Failure to obtain informed consent Study procedures initiated before informed consent Omitting study procedure(s) required by approved protocol Drug dispensing/dosing error Failure to securely control the study product Deviation necessary to eliminate an apparent immediate hazard to a participant Major Protocol Deviations/Violations Protocol Deviations Unanticipated problems involving risk to participants or others

Don t report minor protocol deviations/violations to the IRB/REB Minor Protocol Deviations/Violations Protocol Deviations Unanticipated problems involving risk to participants or others Examples of possible minor protocol deviations/violations: Study visit(s) or study procedure(s) conducted out of timeframe Failure to initial every page of a consent form Participant failure to return study diaries Other protocol deviations/violations that only affect logistical or administrative aspects of the study

What events to report a closer look Serious adverse events Major protocol deviations Other reportable events as defined by Quorum

Additional reportable events Adverse Audit or Enforcement Action(s) Adverse audit results from a sponsor audit FDA Form 483 or Warning Letter Suspension, restriction, reprimand, etc. regarding a medical license Recalls / Withdrawals / Clinical Holds Early Study termination Regulatory Agency or Sponsor marketing withdrawal FDA partial or complete clinical hold FDA Public Health Advisory Participants complaints regarding an alleged breach of the rights, safety, or welfare of the participants or others, or integrity of the study. Reports, publications, or interim results or findings Incarceration of a participant Breach of confidentiality (e.g., loss of study records, breach of a secured database, disclosure of PHI not covered by HIPAA authorization) Research personnel misconduct New or updated product information safety information (e.g., revised Investigator Brochure, device manual, or product label/package insert) Data Safety Monitoring Board report

Must an investigator report other events to the IRB/REB? An investigator should maintain records (such as logs or line listings) of all adverse events, protocol deviations, etc., according to instructions from the sponsor or site monitor At the time of periodic site review, the investigator should report to the IRB/REB whether the investigator believes the study or consent form should be modified in light of these events Do not submit logs or line listings of non-reportable adverse events, minor protocol deviations/violations, etc., to the IRB/REB.

What if the Sponsor instructs investigators to submit all AEs to the IRB/REB? If Quorum receives a report about an event that is not reportable under our policies, Quorum will generally issue an acknowledgment of receipt to the site with a reminder that Quorum does not require reporting of such events.

Review: Report only unanticipated problems All Problems Encountered During a Research Study Unanticipated problems involving risk to participants or others Protocol Deviations Adverse Events

Review: Examples of unanticipated problems involving risk to participants or others that should be reported Do report these types of events: Serious Adverse Event Major Protocol Deviation/Violation Complaints Participant incarceration Adverse Audit or Enforcement Action(s) Breach of confidentiality Recalls / Withdrawals / Clinical Holds New or updated study product safety information Research personnel misconduct Protocol Deviations Unanticipated problems involving risk to participants or others Adverse Events Reportable Events

Review: Examples of non-reportable events All Problems Encountered During a Research Study Do not report these types of events: Minor protocol deviation/violation Adverse event that does not meet reporting criteria Unanticipated problems involving risk to participants or others Non-Reportable Events Protocol Deviations Adverse Events

Use one form to report all reportable events Safety Information and Unanticipated Problem Report for SAEs, major protocol deviations/violations, unanticipated events or other reportable events reported by the Sponsor to the investigator (MedWatch Reports, IND Safety Reports, etc.)

For more information Please link to Quorum s website for more guidance on safety reporting and to find Quorum s reporting forms: http://www.quorumreview.com/sites/safety/